Archimed Diagnostics – the diagnostics team of France‑based global healthcare private equity specialist Archimed – has acquired Stago, a world leader in haemostasis analysis. Stago, headquartered in France, develops and manufactures equipment and reagents used to diagnose blood coagulation disorders. The company was purchased through an undisclosed mix of equity and unitranche debt.
La Caisse, a global investment group, is joining the transaction as a minority shareholder, alongside Stago’s leadership team, which is also taking a minority stake.
The deal marks a new chapter for Stago.
“Our aim is to provide Stago with the resources it needs to accelerate global growth and reinforce its leading position as a pure player with unrivalled expertise,” says Archimed managing partner Vincent Guillaumot. “Stago has a pipeline of innovative products that should allow its revenues and profits to grow well above industry averages,” adds Archimed partner Antoine Faguer.
The founding Viret family chose to transfer ownership to Archimed to support the company’s next phase of expansion. Archimed brings experience in supporting high-potential companies. Its sector positioning and long-term approach offer Stago a suitable framework to reach a new milestone.
“In addition to financial muscle, Archimed and La Caisse have the operational sophistication and discretion to help us grow at a pivotal moment in our company’s history,” says outgoing CEO Jean‑Claude Piel, who will retire from his role and become chair of the Scientific and Technology Monitoring Committee.
Working with Stago’s management team, Archimed plans to expand sales and profitability by building on the company’s gold‑standard product portfolio across both developed and emerging markets. “Archimed’s diagnostics expertise is key for accelerating the efficient rollout of a major new generation of Stago products,” says Philippe Barroux, Stago’s CEO‑elect. “This partnership is all about reigniting innovation at Stago.” Barroux, a 38‑year veteran of the company, currently oversees operations in North America and China.
Diagnostics is a core investment area for Archimed. The firm has completed eight acquisitions in the sector and exited two: Diesse, a pioneer in systems for diagnosing inflammatory and immune disorders, sold to Fremman Capital in 2025, returning 4.6x invested capital after a six‑year hold; and Eurolyser, a point‑of‑care testing specialist, sold to Antech Diagnostics in 2022, generating 6x invested capital, or an 80% annualised return.
Stago represents the tenth investment for Archimed’s MED Platform II fund. All investments from the fund have been first‑time leveraged buyouts for the companies involved. MED Platform II, which closed at €3.5bn in June 2023 after being more than twice oversubscribed, is now approximately 70% deployed following the Stago transaction.
